B&L unveils its latest offerings to Europe

Article

Bausch & Lomb has announced the launch of three new products onto the European market.

Bausch & Lomb has announced the launch of three new products onto the European market, two of which represent the firm's investment in microincision cataract surgery (MICS), whilst the third presents a further enhancement to its Zyoptix refractive surgery portfolio.

The Stellaris system accommodates both bimanual and coaxial MICS techniques, providing a choice in fluidic control with either the Advance Flow System or Advance Vacuum System, maintaining anterior chamber stability and helping to provide surge-free phaco surgery. Meanwhile, enhanced energy phaco delivery with optimized power modulations adds to the integral safety and efficiency of the system. CE marking is pending and expected during the second quarter of 2007.

The Akreos MI-60 lens completes Bausch & Lomb's Millennium MICS platform. The IOL can be implanted through a 1.8 mm incision using a wound-assisted injection technique where the injection cartridge is prevented from entering the anterior chamber. According to B&L, corneal stress is kept to a minimum using this linear technique, because the incision diameter equals the internal diameter of the cartridge. The lens is made from hydrophilic acrylic and is 30% thinner than the original Akreos AO design.

Finally, the Zyoptix XP Epi Separator, for use with the Zyoptix XP microkeratome handpiece, consists of a proprietary epi head for corneal applanation and a single-use epi separator, which work together to create epithelial flaps in around 12 seconds. It is designed to delivers a precise edge that lifts the epithelium smoothly, leaving a smooth Bowman's layer free of defects and stromal incisions. The device allows the microkeratome to support both LASIK and Epi-LASIK procedures.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.